Table 4 Treatment choice related to breast and ovarian cancer risk at T1 and T2 (for the DA and control groups) or T3 (for the DA_b and DA_a groups)
From: Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation
| Â | DA | Control | DA_b | DA_a |
|---|---|---|---|---|
Treatment choice related to bc risk at | T1 | T1 | ||
 Prophylactic mastectomy | 61 (35) | 53 (31) | 17 (37) | 8 (20) |
 Breast cancer screening | 92 (53) | 103 (60) | 24 (52) | 30 (73) |
 Undecided | 20 (12) | 15 (9) | 5 (11) | 3 (7) |
|  | χ2=1.89; P=0.39 | χ2=4.13; P=0.13 | ||
Treatment choice related to bc risk at | T2 | T3 | ||
 Prophylactic mastectomy | 69 (41) | 55 (32) | 18 (40) | 8 (21) |
 Breast cancer screening | 80 (47) | 104 (61) | 26 (58) | 29 (74) |
 Undecided | 21 (12) | 11 (7) | 1 (2) | 2 (5) |
|  | χ2=7.84; P=0.02 | χ2=3.94; P=0.14 | ||
Treatment choice related to oc risk at | T1 | T1 | ||
 Prophylactic oophorectomy | 112 (66) | 105 (62) | 27 (61) | 21 (51) |
 Ovarian cancer screening | 36 (21) | 44 (26) | 10 (23) | 15 (37) |
 Undecided | 21 (13) | 20 (12) | 7 (16) | 5 (12) |
|  | χ2=1.05; P=0.59 | χ2=1.98; P=0.37 | ||
Treatment choice related to oc risk at | T2 | T3 | ||
 Prophylactic oophorectomy | 122 (73) | 107 (63) | 34 (81) | 22 (56) |
 Ovarian cancer screening | 24 (14) | 48 (28) | 6 (14) | 14 (36) |
 Undecided | 21 (13) | 14 (8) | 2 (5) | 3 (8) |
|  | χ2=10.37; P=0.01 | χ2=5.87; P=0.05 | ||
